FLODROVÁ, Eva, Jan JUŘICA, Richard BARTEČEK, Renata GAILLYOVÁ and Alexandra ŽOURKOVÁ. Molecular genetic identification of the major CYP2D6 alleles and utilization in psychiatric treatment of depression. European Journal of Human Genetics. London: NATURE PUBLISHING GROUP, 2009, vol. 2009, 17 Supp2, p. 221. ISSN 1018-4813.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Molecular genetic identification of the major CYP2D6 alleles and utilization in psychiatric treatment of depression
Name in Czech Molekulárně genetická identifikace alel CYP2D6 a její využití v léčbě deprese
Name (in English) Molecular genetic identification of the major CYP2D6 alleles and utilization in psychiatric treatment of depression
Authors FLODROVÁ, Eva, Jan JUŘICA, Richard BARTEČEK, Renata GAILLYOVÁ and Alexandra ŽOURKOVÁ.
Edition European Journal of Human Genetics, London, NATURE PUBLISHING GROUP, 2009, 1018-4813.
Other information
Type of outcome Article in a journal
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.564
Organization unit Faculty of Medicine
UT WoS 000258855500442
Tags International impact
Changed by Changed by: doc. PharmDr. Jan Juřica, Ph.D., učo 14537. Changed: 25/1/2010 10:34.
Abstract
The gene CYP2D6 encodes enzyme involved in biotransformation of psychotropics in psychiatric treatment. The Caucasian population has been grouped in according to the enzymatic activity as poor, intermediate, effective and ultrarapid metabolizers. The determination of metabolic activity prior the dose adjustment could be really useful in some cases. The methodical approach of genotyping is based on long PCR and subsequent sequencing. These standard methods are combinated with RealTimePCR and High Resolution Melting analysis (HRM) using Light Cycler 480 System. Recently is possible to detect the most frequent null alleles 3* 4* 6* 7* and 8*. Allele 5* could be detected by using agarose electrophoresis or UPL probes. HRM analysis has been performed for the most frequent SNPs in CYP2D6 gene as a fast cheap and reliable method for pre-genotyping. O-demethylation of dextromethorfan was used for metabolic activity assesment. The concentrations of marker and metabolite in the urine were determined by HPLC assay. The phenotypes PM and EM were distinguished by using 0,3 antimode. The clinical data were analyzed and compared with genotype and phenotype result. This paper provides an overview of current technologies available for CYP2D6 genotype and phenotype testing and the result of testing of the group of 91 patients, treated with Paroxetine. The effect of Paroxetine treatment on CYP2D6 is summarized in Table 1. Supported by research project MSM 0021622404 (2005 - 2011)
PrintDisplayed: 22/6/2024 21:04